FDA reconsiders Avandia safety problems
FDA is reviewing new data and reports on the safety of GlaxoSmithKline's blockbuster diabetes drug Avandia, and will present findings at a public meeting this summer.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.